Inhaled corticosteroids: the last 5 years

Author(s): Hengameh H Raissy, H William Kelly

This review will highlight new information on the use of inhaled corticosteroids (ICSs) for management of asthma with regard to long-term side effects and new treatment approaches. Variability in response to ICSs has been increasingly recognized and contribution of pharmacogenomic, phenotypes and environmental factors have been identified and discussed here. As ICSs remain the cornerstone of persistent asthma management, the CAMP trial provides more data in long-term adverse effect of ICSs. In order to minimize the side effects of ICSs, different asthma management approaches have been proposed in different patient populations. In addition, potential advantages of fine particle ICSs for improving small airway disease have been discussed.